|
Printable version |
From: | "Malcolm Cameron" <malharcameron@hotmail.com> |
Date: | Mon, 05 May 2003 16:30:00 +1000 |
Snoopy if you had bought and held chemeq from float you would have been very successfull but with there high minimum entry quantities in a lot of floats in the australian market at the time it would have been to many eggs in one basket regards Malcolm >From: "tennyson@caverock.net.nz" <tennyson@caverock.net.nz> >Reply-To: sharechat@sharechat.co.nz >To: sharechat@sharechat.co.nz >Subject: [sharechat] My Biotech Investment Strategy Revealed >Date: Mon, 05 May 2003 17:55:47 +1200 > > >Hi All, > >I see that no-one has responded to my challenge on how to become a >successful investor in Biotechnology. So here is my take on the topic. > >For investment in biotechnology I give equal weighting to both the >science behind the technology being developed, and the business plan >behind commercializing that technology. These being my two >requirements, you can see that none of the science seed research >projects grown into companies make it onto my radar screen. IMO, >there is no point in having the best science in the world if you do not >have the sales channels in place to market the product you are >producing. > >My initial foray into biotechnology saw me identify a company with good >science and a good sales force ready to exploit the product. I was >patient and waited for the stock to lose any bubble in its share price (or >so I thought, the share price halved), then I moved in and bought the >stock. > >Not long after that the share price halved again...... > >After this sobering lesson I decided that perhaps I wasn't the hot biotech >stock picker I thought I was. The company did move into profit (a rare >thing for a biotech, so at least my judgement wasn't totally misplaced), >but in no way did it achieve the kind of results that would have justified >my purchase price. Until, that is, around 1999 at the height of the >NASDAQ boom where I had the good fortune to have my shares taken >over. > >So all ended well and I did end up with a small profit on this investment. >To this day, I don't regard my original investment strategy as unsound. >But I have given up on my quest to become a hot biotech stock picker. I >stand by my assertion in a previous post that investment in >biotechnology is at best a zero sum game, which amounts to a >guarantee that biotechnology investors as a group will lose in the long >run. > >However, what if an investor in the commercial world publicly identifies a >biotech research company that has commercial promise and acts? And >what if I could get in on this deal at virtually no cost? Well, a >couple >of months ago I got in on just such a deal on these terms. I am >referring here to the Wrightson's buy into Genesis Research and >Development. > >I still have the Genesis Research and Development Prospectus and it >has duly achieved an honoured(?) position in my 'library of shame'. >GEN was always going to be a long-shot and the big weakness I saw in >the prospectus (which was why I didn't invest) was that I didn't see a >satisfactory strategy in the offing to bring any products developed to >market. However, bringing product to market is exactly what WRI does. >So when WRI bought into Genesis, at a very good price (less than the >cash value of the bank deposits) I sat up and took notice. > >Genesis Research is still a cash burner, so buying into the company >even at a good price means that it is not guaranteed that this will be a >good investment. However the price paid: > >0.1542 x 5.75m shares x $1.31 equates to $1.1615m > >Given that there are 134.2m WRI shares out there this equates to >around 1c per share. In other words it would not be catastrophic to WRI >if this entire investment ended up flushed down the dunny. On the >upside a closer co-operation between WRI (who have their own crop >research centre out at Lincoln) and GEN could lead to significant >rewards, especially as WRI *does* have the sales channels to get a >commercial reward from any successful product development. It has >since been announced that GEN is to split into two, one half >concentrating on the 'health business' and the other the 'plant business'. >What is the bet that WRI will be driving the latter half? > >>From the Wrightson perspective the risk reward equation looks good. > >Downside: 1c per share. > >Upside: Whatever the market thinks is a suitable premium for a >successfully developed high tech product. IMO any upside is more >likely to be reflected in a changed market perception that WRI is no >longer a commodity company with cyclical assets. Changing the >perception of WRI is a long term objective of MD Dr Alan Freeth and >could result in a major re-rating of the WRI share price. > >In summary I feel the risk/reward trade off for investing in WRI is more >attractive than ever. At $1.11 (and a yield of 15%) WRI is, IMO still >*the* stand out investment on the NZSE. I don't know when the market >will finally realize how cheap WRI is, but I certainly wouldn't want to be >underweight in WRI waiting for it to happen. This is why I topped up at >seemingly insane price of $1.01 on 31st March 2003! > >SNOOPY > >discl: hold WRI > >But do not hold GEN directly. I'm quite happy to leave the decision of >where my indirect holding in biotechnology company GEN goes, in the >capable hands of Dr Freeth and the WRI board. > >-- >Message sent by Snoopy >on Pegasus Mail version 4.02 >---------------------------------- >"Stay on the upside of the downside, >Anticipate the anticipation!" > > > > >---------------------------------------------------------------------------- >To remove yourself from this list, please use the form at >http://www.sharechat.co.nz/chat/forum/ > _________________________________________________________________ Hotmail now available on Australian mobile phones. Go to http://ninemsn.com.au/mobilecentral/hotmail_mobile.asp ---------------------------------------------------------------------------- To remove yourself from this list, please use the form at http://www.sharechat.co.nz/chat/forum/
Replies
|